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Abstract: PA28 is a -interferon-induced 11S complex that associates with the ends of 
the 20S proteasome and stimulates in vitro breakdown of small peptide substrates, but not 
proteins or ubiquitin-conjugated proteins. In cells, PA28 also exists in larger complexes 
along with the 19S particle, which allows ATP-dependent degradation of proteins; although 
in vivo a large fraction of PA28 is present as PA28-20S particles whose exact biological 
functions are largely unknown. Although several lines of evidence strongly indicate that 
PA28 plays a role in MHC class I antigen presentation, the exact molecular mechanisms 
of this activity are still poorly understood. Herein, we review current knowledge about the 
biochemical and biological properties of PA28 and discuss recent findings concerning its 
role in modifying the spectrum of proteasome’s peptide products, which are important to 
better understand the molecular mechanisms and biological consequences of PA28 activity. 
Keywords: PA28; proteasomes; immunoproteasomes; protein degradation; MHC class I 
antigen presentation; epitopes; antigenic peptides 
 
1. MHC Class I Antigen Presentation 
The continual presentation of intracellular proteins fragments on major histocompatibility complex 
(MHC) class I molecules is a process that allows cytotoxic CD8+ T lymphocytes (CTLs) to identify 
and selectively eliminate cells that synthesize foreign (e.g., viral) or abnormal (e.g., oncogene products) 
proteins [1,2]. The vast majority of MHC class I-presented peptides (known as antigenic peptides or 
epitopes) are generated during the degradation of mature proteins or defective ribosomal products 
(DRiPs) by the ubiquitin-proteasome system (UPS) [3,4]. These peptides are then translocated through 
TAP transporters [5] to the endoplasmic reticulum (ER) where they bind to MHC class I heterodimers 
and are delivered to the cell surface [6]. The active form of the proteasome, which appears to degrade 
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most cellular proteins, is the 26S proteasome [7,8]. This large (2.4 MDa) and abundant multi-subunit 
proteolytic complex consists of the 20S proteasome, in which proteins are degraded, capped at  
one or both ends by the 19S regulatory particle, which is responsible for recognizing, unfolding, and 
translocating polyubiquitinated (and some non-ubiquitinated, e.g., denatured) substrates into the 20S 
internal proteolytic cavity [9]. The 20S proteasome is a barrel-shaped structure composed of four 
stacked heptameric rings. The two outer rings consist of -subunits, while the two central rings are 
made up of -subunits [10]. In most cells, the proteolytic activity of the 20S proteasome is located at 
subunits 5 (X), 2 (Z), and 1 (Y) of the core particle. However, lymphoid cells and cells exposed to 
cytokines such as IFN- alternatively express three homologous subunits (5i/LMP7, 2i/MECL-1, 
1i/LMP2), which replace the constitutive ones in newly assembled so-called immunoproteasome 
particles [11]. A variety of studies have demonstrated that incorporation of these INF--induced subunits 
quantitatively modifies proteasomal cleavage preferences and enhances the production of a significant 
number of antigenic peptides, although there are examples of epitopes that are generated with lower 
efficiency, or which are not released, by immunoproteasomes [12]. In any case, the recent generation 
of transgenic mice lacking all three proteasomal catalytic -immune subunits clearly demonstrated the 
pivotal role that immunoproteasomes play in the generation of MHC class I ligands [13]. Additionally, 
immunoproteasomes have been shown to be important for efficient cytokine production [14] and have 
been implicated in a number of pathological disorders such as cancer and neurodegenerative and 
autoimmune diseases [15–17]. Finally, it has been recently demonstrated that 26S immunoproteasomes 
possess the capacity to hydrolyze basic proteins (such as Histones and Myelin Basic Protein) at greatly 
increased rates compared to constitutive proteasomes [18]. 
2. Proteasome Activator PA28 
2.1. Structure 
Another INF--inducible UPS component that affects MHC class I antigen presentation is PA28 
(also termed REG or 11S), a ring-shaped 180 kDa multimeric complex that binds, in an ATP-independent 
manner, to the two ends of the 20S proteasome and substantially enhances its ability to degrade short 
peptide substrates, but not proteins or ubiquitin-conjugated proteins [19,20]. In addition, PA28 can also 
associate with the free end of asymmetric 26S proteasomes (19S-20S) to form so-called “hybrid 
proteasomes” (19S-20S-PA28) [21–24] that hydrolyze tri- and tetra-peptides at higher rates than canonical 
26S particles [21,23]. In mammals, PA28 is composed of two homologous subunits, namely PA28 
(REG or PSME1) and PA28 (REG or PSME2), both of which are induced by -interferon [25–31]. 
A third member of PA28 family is PA28 (also known as REG, 11S or Ki antigen), which is  
a nuclear antigen that is not induced by INF- and not involved in MHC class I antigen presentation. 
The biochemical and biological properties of PA28 has been reviewed elsewhere [32], and consequently 
will not be considered in detail. 
PA28 and PA28 have an apparent molecular weight of 28 kDa on SDS-PAGE electrophoresis 
and share a nearly 50% amino acid sequence identity [25,29,33]. Based on the crystal structure of 
PA28 [34], the overall secondary structure of PA28 proteins is composed of four long -helices  
of 33–45 residues in length that are involved in intra- and intermolecular interactions. The linker 
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sequence between helices 2 and 3, which is highly conserved in PA28  and  subunits, is designated 
the “activation loop” since it is responsible for stimulation of proteasome peptidase activities [35].  
A second region of the molecule involved in the activation of 20S proteasome is the 10 residue  
C-terminal tail, which provides binding energy for PA28-proteasome association [36–38]. Finally,  
the linker between helices 1 and 2 is composed of sequences that are highly divergent between PA28  
and  subunits and for this reason are known as “homolog specific inserts” [39]. Although these inserts 
are not resolved in the X-ray structure of PA28, presumably since they are flexible, it is almost 
certain that they protrude from the upper surface of the PA28 ring [30]. 
PA28 has been reported to be phosphorylated in vivo on serine residues [40,41] and phosphorylation 
was believed to be indispensable to activate proteasome peptidase activities [41]. Considering, 
however, that nearly all in vitro studies concerning the biochemical properties of PA28 have been 
performed using the recombinant protein expressed in E. coli (which in the vast majority of cases  
are not competent for phosphorylation of recombinant proteins), it is clear that phosphorylation is not 
essential for the stimulatory activity of PA28, while in vivo it may exert more subtle and yet 
unidentified regulatory functions. Moreover, binding of PA28 to calcium has also been described 
although the physiological significance of this observation remains an open question [42]. 
While it is clear that at least in vitro recombinant PA28 can form a heptameric ring [34,43] and 
recombinant PA28 is a monomer [35,39], the subunit stoichiometry of native PA28 has been 
initially reported [26,38] to be a hexamer (33). However, subsequent studies indicated that heteromeric 
PA28 is a heptamer formed by the association of three  subunits and four  subunits [44,45]. Electron 
microscopy images show that PA28 forms a cap on the end of 20S particle by interacting with 
proteasome -subunits [46]. This cap is about 10–11 nm wide at the base, where it attaches to 
proteasome  subunits, and 7–8 nm long from the base to the tip. EM data also indicate that PA28 
contains a central channel that apparently traverses it entirely to the central pore of proteasome -ring. 
Accordingly, the crystal structure of recombinant PA28 at 2.8 Å resolution reveals a heptameric ring 
traversed by a central aqueous channel with a diameter of 30 Å on the face contacting the proteasome 
and 20 Å on the other [34]. 
2.2. Role in MHC Class I Antigen Presentation 
The effects of PA28 on antigen processing and CD8+ T-cell responses are still unclear and 
controversial [2,30]. Professional antigen presenting cells generally express PA28 at high levels, 
which is in agreement with a possible function of this complex in MHC class I antigen processing [47,48]. 
Accordingly, expression of PA28 alone [49,50] or PA28 [50–54] has been reported to enhance 
MHC class I-presentation of some, but not all, antigens. Furthermore, cells lacking this complex have  
a reduced ability to generate certain antigens [55], and recent studies identified the second most 
important UPS component in PA28 (surpassed only by 5i/LMP7) for production of MHC class I 
ligands [56], although its effects seem to be restricted to specific MHC class I alleles [57]. 
Although concerted expression of PA28  and  and proteasomal 1i, 2i and 5i subunits 
following INF- induction leads to the formation of PA28-20S immunoproteasomes in vitro and  
in vivo [22,24,26,31,55,58–64], however PA28 can also be detected in cells, tissues and organs  
that lack immunoproteasomes like erythrocytes, muscle and brain [19,20,58–61,65,66]. It is, therefore, 
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conceivable that PA28 can exert its biological function(s) also in association with constitutive 
proteasomes, probably related to its capacity to substantially modify the pattern of proteasomal 
peptides products. Further studies will be required to assess whether the changes in the patterns of 
peptides generated from proteins following binding of PA28 with 20S and 26S constitutive are 
similar to those already identified for its association with 20S and 26S immunoproteasomes [18]. 
2.3. Biochemical Properties 
2.3.1. Hydrolysis of Fluorogenic Peptide Substrates 
As pointed out above, PA28 was originally identified due to its capability to markedly stimulate 
peptidase activities of the 20S proteasome, as measured using short fluorogenic model substrates.  
In particular, kinetic studies revealed that PA28 increases Vmax and reduces Km for peptide hydrolysis 
by proteasomes [19,20]. Subsequent detailed biochemical analysis demonstrated that the native and 
recombinant PA28 subunit is able to activate all three main proteasomal peptidase activities [35,39,65,67]. 
Nonetheless, the precise biochemical functions of PA28 are still unclear and a matter of debate. 
While it is well established that, by association with the  subunit, PA28 strongly enhances the 
affinity for the proteasome of the PA28 heterocomplex [38,65,67], whether the  subunit by itself 
activates the 20S particle is controversial, as acknowledged in several studies [35,36,39,52], but 
excluded in others [31,65,67]. Paradoxically, in one investigation PA28 was reported to activate 
proteasomes at high concentrations, but behaves as an allosteric proteasome inhibitor at low 
concentrations [68]. To investigate this issue, we checked the effect of our standard preparation of 
recombinant PA28 on proteasomal chymotryptic activity. From our experiments, it is clear that 
PA28 is able to associate with the  subunit and to greatly increase its affinity for the 20S proteasome, 
but by itself it does not exert any stimulatory effect on proteasome chymotrypsin-like activity (Figure 1). 
Figure 1. Effect of PA28, PA28 and PA28 on the chymotrypsin-like activity of  
20S immunoproteasome. Assays were carried out in continuo at 37 °C in 500 L of buffer 
reaction 20 mM Tris-HCl pH 7.5, 0.2% (w/v) BSA, containing 100 M of Suc-LLVY-AMC. 
For each assay, 4 ng of 20S were used. 
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Concerning the exact molecular mechanisms of proteasome activation by PA28, a variety of 
biochemical actions have been proposed, including allosteric modification of the 20S proteasome active 
sites [20,69] or non-catalytic modifier sites [69], stimulation of peptide entry into the particle [20,52,70], 
stimulation of peptide exit [52,71], and facilitating the binding of proteasomes to chaperones or to 
components of the endoplasmic reticulum [30]. In particular, PA28 has been often proposed to 
enhance hydrolysis of short peptides by inducing long-range conformational changes in proteasomal 
active sites. In fact, biochemical data indicates that proteasome proteolytic sites are allosterically 
regulated [36,72–75] and that their modification leads to gate opening [76–78]. Furthermore,  
an allosteric pathway linking the PA26 (the PA28 homologue in trypanosomes) binding sites with the 
active sites in the T. acidophilum 20S proteasome has been recently described [79]. On the other hand, 
crystallographic studies unambiguously showed that association of yeast 20S with PA26 does not 
induce any structural modification of proteasomal catalytic  subunits [71], thus disproving an 
allosteric mechanism for its stimulatory effect. It remains, however, possible that subtle changes in  
the -rings of 20S proteasomes induced by PA28 are lost in the rigid crystal structure of PA26-20S  
but might be detectable with other techniques (e.g., NMR or EM) [80,81]. PA28 has also been reported 
to enhance the ability of 20S proteasomes to make correct C- and N-terminal cleavages in longer 
oligopeptides in vitro in order to generate class I presented epitopes [82,83]. However, other studies 
indicate that proteasomes generate N-extended precursors of antigenic peptides [84] that are trimmed 
to their presented epitopes by cellular aminopeptidases [85–90]; this N-terminal trimming is also 
stimulated by -interferon [86,90,91], thus strongly questioning the in vivo relevance of the double  
cut model. Lastly, PA28 was reported [92] to be essential for assembly of immunoproteasomes, but 
subsequent studies failed to confirm this finding [55,93]. 
2.3.2. Gate Opening Mechanism 
In the crystal structure of PA26 solved by Hill and coworkers [71], the binding of PA26 was found 
to open the gate on the channel in the proteasome -ring through which substrates enter [94]  
and products exit [70]. Specifically, PA26 C-terminal residues dock into pockets between adjacent 
proteasome  subunits and, by forming hydrogen bonds and a salt bridge between the C-terminal 
carboxylate of the activator and a highly conserved proteasome lysine side chain (Lys 66), provide 
binding energy for PA26-20S complexes [71,95]. Binding to the C-termini of PA26, however, is not 
sufficient to activate the 20S proteasome, which requires the activation loop that forms a seven-fold 
symmetric circular array that interacts with the base of the N-terminal gating residues of the seven 
proteasomal  subunits. In particular, a glutamate side chain (Glu 102) in each PA26 subunit activation 
loop contacts and repositions a proline residue (Pro 17) of 20S  subunits located above the surface of 
the proteasome. This interaction triggers gate opening by disrupting packing and hydrogen bonding 
interactions of the asymmetrical closed conformation and by widening the pore opening to a more 
symmetrical arrangement that allows a belt of intersubunit contacts to form around the circumference 
of the opening [96,97]. 
On the basis of these structural observations, PA28 was predicted to lead to attenuation of 
proteasomal processivity and consequent release of peptide products of greater mean length [71],  
as occurs on deletion of the -gate [70]. Since most peptides released by proteasomes are too short to 
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bind to MHC class I molecules [84,98–101], the generation of larger products would be expected to 
enhance the fraction of products capable of serving in antigen presentation, either directly or after 
trimming by aminopeptidases in the cytosol [89,102] or endoplasmic reticulum [86–88,90,103]. 
However, since not only PA28 but also the 19S regulator can induce the opening of the 20S core 
particle central gate [104], it remains unclear whether the above-mentioned structural observations can 
explain the specific effects of PA28 on substrate cleavage and, consequently, on antigen presentation. 
2.3.3. Effects of PA28 on Protein Degradation 
In this respect, it is clear that a full understanding of the specific biochemical functions of PA28 
requires quantitative information on the rates of protein substrate hydrolysis and generation of peptide 
products by PA28-containing immunoproteasomal species. To address this important issue, we recently 
performed a systematic analysis of the entire spectrum of peptides released during degradation of  
full-length proteins by PA28-20S immunoproteasomes [101]. PA28-20S particles were found to 
hydrolyze proteins at identical, slow rates compared to 20S proteasomes, and to generate higher amounts 
of very short products together with several longer peptides characterized by higher overall hydrophilicity. 
The finding that unstructured polypeptides are hydrolyzed at rates that are nearly 10-fold higher by 
26S compared to 20S and PA28-20S immunoproteasomes is consistent with the notion that the free 
20S particle is a relatively inactive protease since the N-terminal tails of its  subunits obstruct  
the two opposite axial pores through which substrates access the internal catalytic lumen [94].  
This autoinhibited state is relieved when the 20S core particle binds to activators such as 19S or PA28 
that displace, in an ATP-dependent and independent manner, respectively, the N-terminal tails thereby 
opening an axial channel in the  annulus [70,71]. However, the latency of unliganded 20S proteasome 
is not absolute since, even in the absence of artificial treatments (e.g., heating or presence of low 
concentrations of detergents or chaotropic agents) that are known to activate it [10], the 20S core 
particle degrades proteins at detectable and reproducible rates, probably involving transient and/or only 
partial channel opening [70,76–78]. Surprisingly, despite the fact that the open-channel conformation 
of the gating residues induced by ATP-dependent and independent activators appears to be identical [105], 
our data show that PA28-20S immunocomplexes hydrolyze proteins at the same rates as 20S 
immunoproteasomes, but much less efficiently than 26S immunoproteasomes. While on one hand  
this confirms initial reports on the biochemical properties of PA28 [19,20,65], it is difficult to 
reconcile with the known role of the proteasomal gate in controlling accessibility of substrates into the 
lumen of the 20S particle. In fact, opening of the axial channel by deletion of the N-terminal tails of 
eukaryotic [70,106] or archaeal [107] proteasomal  subunits results in strong enhancement of  
the degradation rates of unfolded proteins, therefore suggesting that unstructured substrates can freely 
access the internal proteolytic chamber of the 20S particle simply by passive diffusion through a fully 
open gate. Furthermore, although it has been proposed that translocation of completely unstructured 
proteins might require a driving force produced by ATP hydrolysis [108], subsequent studies 
demonstrated that once the polypeptide chain is unfolded its transit through the ATPases ring can 
occur by passive diffusion, in which retrograde movement is probably prevented by a Brownian ratchet 
mechanism [109]. In light of these data, the inability of PA28 to enhance hydrolysis rates of loosely 
folded proteins is surprising. It can be speculated that the presence of a supplementary multimeric ring, 
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sitting at the proteasomal outer  surface, might impose an extra constraint to the completely free 
diffusion of large, although linear, polypeptide chains into the internal proteasomal lumen. From this 
point of view, transit thorough the pore of open gate mutants might not perfectly reflect passage across 
the PA26/28 central channel. In fact, the crystal structure of PA28 shows that the aqueous channel 
through the heptamer has a diameter of 20 Å at its minimum, which is theoretically wide enough for 
passage of unfolded proteins [34]. However, the homolog-specific inserts present between helices 1 
and 2, which are not resolved in the crystal structure, most likely form a ring-like collar on the upper, 
non-proteasome binding surface of the PA28 heptamer. Although several studies have shown that 
these loops do not restrict passage of tri- or tetra-peptide fluorogenic substrates [35,67], recent 
investigations have demonstrated that they can hinder the transit of longer peptides, and conceivably of 
proteins as well, through the PA28 channel [44]. In fact, we demonstrated that 20S and PA28-20S 
immunoproteasomes hydrolyze proteins at exactly the same slow rates, which implies that denatured 
substrates transit through the partially or transiently open gate of unligated 20S and the fully open 
channel of PA28-20S particles with comparable efficiency. However, it cannot be excluded that 
PA28 might selectively enhance degradation of some specific substrates that are yet to be identified, 
as has been unambiguously demonstrated for PA28 [110–113]. 
2.3.4. Effects of PA28 on Peptide Products Generation 
Although PA28 is unable to enhance rates of protein degradation by proteasomes, its association 
with the 20S particle was found to lead to substantial changes in the patterns of peptides generated, 
which greatly differ from those produced by 20S and 26S immunoproteasomes [101]. In fact, only ~10% 
of peptides generated by 20S and 26S immunoproteasomes were found to be 8–10 residues long [101], 
which is the appropriate length to bind MHC class I heterodimers. Most importantly, association of 
PA28 with the ends of 20S immunoproteasomes does not increase the fraction of 8–10 residue 
peptides generated, but reduces it to 6% of the total. Moreover, the fraction of peptides longer than  
10 amino acids, which might serve in MHC class I antigen presentation only after appropriate 
trimming by aminopeptidases in the cytosol or ER, is larger for 20S than for 26S immunoproteasomes; 
binding of PA28 to the 20S particle dramatically reduces the overall efficiency of generation of 
these longer products. It is thus clear that PA28 does not act simply by expending the fraction of 
proteasomal products that can be accommodated in the groove of MHC class I molecules directly or 
after trimming. In this regard, it is worth noting that both 20S and 26S immunoproteasomes display a 
similar high propensity to release 8–10 residue long products, although 20S has also an increased 
capacity to generate longer fragments [101]. However, correct evaluation of the overall efficiency of 
different immunoproteasome species in producing peptides with a size potentially suitable for class I 
antigen presentation requires normalization of their rates of generation with those of substrate 
hydrolysis. Therefore, since in vitro 26S immunoproteasomes were found to degrade unfolded proteins 
at 10-fold higher rates than 20S and PA28-20S [84,101,114], it is evident that 26S holoenzymes  
are potentially the most efficient immunoproteasomal species in terms of generating higher amounts of 
peptides with the correct size to serve in MHC class I antigen presentation either directly or after 
aminopeptidase trimming. 
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2.3.5. PA28 as a Smart Sieve 
Surprisingly, PA28-20S immunoproteasomes were found to display a reduced ability to generate 
longer products that, in principle, might depend upon conformational changes in proteasomal active sites. 
This hypothesis has already been suggested to explain the biochemical properties of PA28 [36,72,75], 
and specifically its ability to stimulate coordinated dual cleavages of short synthetic peptides (typically 
19–25 residues long) by 20S particles [82,83]. This possibility, however, seems unlikely for PA28-20S 
immunoproteasomes since, as already pointed out, association with PA26 does not induce any structural 
modification of proteasomal catalytic  subunits [71]. Alternatively, PA28 might primarily act as  
a molecular sieve that retains longer protein fragments inside the 20S proteolytic chamber until they 
are cleaved to peptides that are small enough to diffuse to the outside. This later model would be 
consistent with detailed kinetic analyses showing that PA28 exerts its activating influence by enhancing 
bi-directional passage of short (3–4 residues) peptides [52] and with an important in vitro/in silico 
study that identified one of the major factors involved in the enhancement of double cut efficiency 
induced by PA28 in a reduced efflux of longer peptides out of the 20S particle [115]. Furthermore,  
it was recently shown that a PA28 complex lacking the unstructured and highly mobile PA28 loops 
surrounding the central pore of the heptameric ring cleaves substrates longer than a nonpeptide more 
efficiently than wild type PA28. On these bases, it was hypothesized that the flexible loops of PA28 
might act as gatekeepers that block the exit of longer peptides from the proteolytic chamber [44]. 
Selectivity based exclusively on peptide size, however, cannot account for the overall effects of PA28 
on the patterns of proteasome products observed by Raule et al. [101]. In fact, quantitation of products 
demonstrated that several individual peptides with a length of 8–23 residues are released in much 
higher amounts by PA28-20S than by 20S or 26S immunoproteasomes [101]. Therefore, PA28 
appears to act as a selective filter that promotes preferential passage of only subset of specific long 
products through its central channel, presumably based on sequence. 
At present, the properties that might allow specific longer peptides to evade the constraint imposed 
by PA28 towards their efflux are not completely clear. However, the finding that products longer than 
seven residues whose generation is strongly enhanced in the presence of PA28 are, on average, more 
hydrophilic than those preferentially released by 20S alone [101], strongly suggests that the passage of 
polar/charged long peptides thorough PA28 might be favored. In this model, PA28 would act as  
a selective “smart” sieve that strictly controls the exit of products from proteasomes on the basis of 
size and sequence (Figure 2). As a result, PA28 would promote preferential efflux from the 20S 
proteolytic cavity of only a reduced number of individual peptides longer than 6–7 amino acids, while 
the majority of the other proteasomal products are retained inside where they are further cleaved to 
smaller pieces before they diffuse outside. In accordance with this model, the central channel of 
PA28 ring is almost completely lined by charged or polar residues [34], and is thus well suited for 
permitting the passage of water soluble peptides. Importantly, this molecular model would be also 
consistent with our findings on 19S-20S-PA28 immunoproteasomes. In this case, the absence of  
a clear difference in size distribution [21] argues that in hybrid proteasomes (as in 26S canonical 
particles) the main route of exit of peptides from the inner proteolytic chamber is regulated by the 19S 
cap, while PA28 would exert its major effect by allowing preferential sorting of selected products 
through its central channel. 
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Figure 2. “Smart” sieve model for biochemical activity of PA28. See text for more details. 
 
2.4. Other Potential Biological Functions 
A full understanding of the exact biological functions of PA28 would undoubtedly represent an 
important achievement, especially in the light of the observation that mammalian cells contain 
significant amounts of PA28-20S immunocomplexes [22,24,26,58–61] whose abundance further 
increases upon INF- stimulation [31,55,62]. In this respect, it seems extremely unlikely that PA28 
functions in vivo to stimulate degradation of cytosolic oligopeptides by proteasomes, because such 
peptides are very rapidly hydrolyzed by other cellular exo- and endo-peptidases [116]. Moreover,  
it has been shown in vitro that peptides released by proteasomes are further cleaved by these 
proteolytic particles at extremely low rates [117], and they are thus unlikely to efficiently compete for 
degradation with proteins, which are much more preferred substrates [118]. 
Importantly, the advantage of PA28-containing proteasomes that generate highly divergent patterns 
of potential antigenic peptides, characterized by profound qualitative and quantitative differences, 
might become relevant under specific pathophysiological conditions especially if favoring a non-canonical, 
ubiquitin-independent, protein hydrolysis pathway. In fact, most of the in vitro studies addressing  
the production of antigenic peptides have focused on degradation by proteasomes of denatured,  
non-ubiquitinated proteins since ubiquitinated proteins are not hydrolyzed by 20S and PA28-20S 
complexes [10,19]. This is likely due to the fact that these particles lack the enzymatic activities 
necessary to remove and/or to unfold polyubiquitin chains that otherwise would sterically block 
translocation of substrates into the proteolytic chamber [119–121]. Although further studies will be 
required to clarify whether the patterns of peptides released are different if a protein substrate initially 
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binds to the 19S regulatory particle through a polyubiquitin chain or directly through an unstructured 
domain, several lines of evidence indicate that in vivo denatured proteins are important, physiological 
substrates for intracellular proteolysis. A large fraction of MHC class I epitopes is derived from  
rapid degradation of DriPs [122–124] in a process that has been shown to be at least partially 
ubiquitin-independent [124–126]. Furthermore, several recent reports indicate that some loosely-folded, 
short-lived regulatory, viral and oxidized proteins are degraded in vivo by the 20S proteasome in  
an ATP- and ubiquitin-independent manner [126–133]. In this regard, a contribution of PA28 in this 
alternative pathway of protein catabolism pathway seems plausible. Moreover, immunoproteasomes 
were recently reported to be strongly induced under conditions of oxidative stress [134], and according 
to several lines of evidence, oxidized proteins are preferentially degraded without ubiquitination by 
20S proteasomes [131] in a process that was reported to be stimulated by PA28 [135–137]. 
Importantly, oxidative damage of DNA is recognized as an important cause of malignant 
transformation and cancer development [138], which emphasizes the importance of efficient MHC 
class I immune surveillance in the presence of oxidative stress. Of note, PA28 was shown to be 
highly induced in a naturally occurring tumor [15]. Under conditions of altered redox homeostasis, 
therefore, the pool of peptides specifically or preferentially released by PA28-20S immunoproteasomes 
might be critical in eliciting an effective CTL response. Furthermore, by enhancing fragmentation of 
the large majority of proteasomal products, but at the same time, by promoting release from the 20S 
particle of specific peptides with a length of eight or more residues, PA28 is likely to exert a profound 
influence on the immunodominance hierarchy of CD8+ responses. Finally, it is also conceivable that 
by promoting release of peptides that apparently cannot serve in class I antigen presentation [101], 
PA28 might exert a regulatory function aimed at blunting excessive cytotoxic responses against 
antigens of self-origin, thus preventing the risk of potentially harmful autoimmune reactions. 
3. Conclusions 
Although PA28 has been discovered more than 20 years ago, its precise biological functions have 
remained somewhat elusive, and despite that several in vitro and in vivo studies have attempted to 
clarify its effects on MHC class I antigen presentation pathway, its role in adaptive immunity is still 
quite unclear. Recent data, however, indicate that the main function of PA28 may be related to its 
capacity to enhance generation by immunoproteasomes of subset of specific more hydrophilic 
peptides. Further studies will be required to unveil the specific role of these hydrophilic products and 
to clarify whether they are favoured in some steps of the MHC class I antigen processing pathway. 
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